News in Gastric Cancer

News from around the world, curated by the Gastric Cancer Foundation.
lonsurf

FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer

Shared in OncLive, the FDA has granted priority review to a supplemental new drug application for TAS-102 (trifluridine/tipiracil; Lonsurf) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.

Read Source
X